ESMO 2017 Highlights in Mesothelioma: Role of Immunotherapy in Second- and Third-Line of Treatment

Speaker: Julien Mazières

Julien Mazières explains that while the first-line standard of care is clear, there are no clear recommendations for 2nd and 3rd line treatments. 

Julien Mazières explains that while the first-line standard of care is clear, there are no clear recommendations for 2nd and 3rd line treatments.

Gerard Zalcman reports on the MAPS-2 trial results testing immunotherapy (single agent or combination) in recurrent mesothelioma. The results of both treatments are very encouraging but not yet mature as the median OS isn’t reached in the combination arm after 15 months of follow-up.

Although this wasn’t a randomised study, Julien Mazieres thinks that it demonstrates the activity of immunotherapy in this setting and hopes that the authorities would now validate its use in pre-treated mesothelioma patients.

 

Abstracts

  • LBA58_PR: Second or 3rd line nivolumab (Nivo) versus nivo plus ipilimumab (IPI) in malignant pleural mesothelioma (MPM) patients: Updated results of the IFCT-1501 MAPS2 randomized phase 2 trial

More resources from ESMO 2017 Congress